The production of IFN-γ by NK-92 cells cultured with increasing concentrations of hIL-21 was assessed. Media from cells incubated with hIL-21 for 24 hours was collected and assayed for IFN-γ by ELISA and the OD450 was determined.

Gallery: Human Interleukin-21 (hIL-21) #8920

The purity of recombinant hIL-21 was determined by SDS-PAGE of 6 µg reduced (+) and non-reduced (-) recombinant hIL-21 and staining overnight with Coomassie Blue.

The production of IFN-γ by NK-92 cells cultured with increasing concentrations of hIL-21 was assessed. Media from cells incubated with hIL-21 for 24 hours was collected and assayed for IFN-γ by ELISA and the OD450 was determined.

Source / Purification

Product Description

>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant hIL-21. Less than 9% is nicked after Arg114 to generate 6 kDa and 10 kDa polypeptides observed in reduced (+) hIL-21.

Molecular Formula:

Recombinant hIL-21 contains no "tags" and the nonglycosylated protein has a calculated MW of 15,463. DTT-reduced and non-reduced protein migrate as 16 kDa polypeptides, with non-reduced having slightly greater mobility due to intramolecular cystines. The expected amino-terminal QGQDR of recombinant hIL-21 was verified by amino acid sequencing.

Bioactivity:

The bioactivity of recombinant hIL-21 was determined by its ability to induce IFN-γ production by NK-92 cells. The ED50 of each lot is between 1.0-6.0 ng/ml.

Product Usage Information

Storage:
Stable in lyophilized state at 4°C for 1 year after receipt. Sterile stock solutions reconstituted with carrier protein are stable at 4°C for 2 months and at -20°C for 6 months. Avoid repeated freeze-thaw cycles.Maintain sterility. Storage at -20°C should be in a manual defrost freezer.